Stromal CD10 expression in invasive breast carcinoma


  • Haval D. Ali Department of Histopathology, Rizgary Teaching Hospital, Erbil, Iraq.
  • Jalal A. Jalal Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Iraq.
  • Ava T. Ismail Department of Clinical Analysis, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
  • Wahda MT. Alnuaimy Department of Pathology, College of Medicine, University of Mosul, Mosul, Iraq.



Invasive breast carcinoma, Stroma, CD10, Immunohistochemistry, Histopathology


Background and Objective: This study aimed to assess the immunohistochemical expression of stromal CD10 in invasive breast carcinoma and determine its relationship with some clinicopathological parameters.

Methods: A cross-sectional study was conducted on 91 female breast cancer cases collected from the archive of pathology department in Rizgary Teaching Hospital and some private labs during the period from January 2012 to August 2015. CD10 expression was detected by immunohistochemistry using labeled polymer and enhanced polymer systems (Dako EnVision™ Flex) Dakoprotocol. The scoring was based on the intensity and percentage of the stained stromal cells. Then CD10 immunoexpression was correlated with the age of patients, tumor size, histopathological types, tumor grade, lymphovascular invasion, lymph node status, and tumor stage.

Results: Stromal CD10 expression was observed in 70.4% of the cases. A statistically significant positive correlation was seen between stromal CD10 and the tumor subtype (P = 0.02), tumor grade (P = 0.025), lymphovascular invasion (P = 0.002), and lymph node status (P = 0.047), however, no statistically significant association was identified between stromal CD10 expression and age, tumor size and tumor stage.

Conclusion: Stromal CD10 is expressed in the majority of cases of invasive breast carcinoma and concerning the positive correlations between stromal CD10 expression and tumor grade, lymphovascular invasion, and lymph node status suggest a strong effect of stromal CD10 expression on aggressive behavior of breast carcinoma.


Metrics Loading ...


- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics 2012. Can J Clin 2015; 65:87-108.

Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2013, National Cancer Institute. Bethesda, MD, http://seer cancer gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.

OECD/European Union 2010: Screening, Survival and Mortality for Breast Cancer, in Health at a Glance: Europe; 2010. OECD Publishing.

American Cancer Society. Breast Cancer Facts & Figures 2015-2016. Atlanta: American Cancer Society, Inc.; 2015. P. 23-6.

Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Can 2010; 17:R245-62.

Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al. Basallikeand triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011; 24:157-67.

De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003; 200:429-47.

Jana SH, Jha BM, Patel C, Jana D, Agarwal A. CD10-a new prognostic stromal marker in breast carcinoma, its utility, limitations and role in breast cancer pathogenesis. Ind J Pathol Microbio 2014; 57:530-6.

Huang WB, Zhou XJ, Chen JY, Zhang LH, Meng K, Ma HH, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. JPN J Clin Oncol 2005; 35:245-50.

Braham H, Trimeche M, Ziadi S, Mestiri S, Mokni M, Amara K, et al. CD10expression by fusiform stromal cells in nasopharyngeal carcinoma correlates with tumor progression. Virch Arch 2006; 449:220-4.

Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham histological grade in invasive breast carcinoma. J Clin Oncol 2008; 26:3153-8.

Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 83:803-19.

Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol 2007; 20: 84-9.

Hosni HN, Abd El-Aziz A, Tabak SA, Elsayed M. Immunohistochemical Study of Stromal CD10 Expression in Mammary Duct Carcinoma. Med J Cairo Univ 2012;80:37-44.

Mohammadizadeh F, Salavati M, Afshar moghaddam N. CD10 expression in stromal component of invasive breast carcinoma: A potential prognostic determinant. J Res Med Sci 2012; 17:S194-9.

Taghizadeh-Kermani A, Jafarian AH, Ashabyamin R, Seilanian-Toosi M,Pourali L, Asadi M, et al. The Stromal Overexpression of CD10 in Invasive Breast Cancer and its Association with Clincophathologic Factors. Iran J Can Prev 2014; 7:17-21.

Masaki T, Keiichi I, Masahiko K, Miki I. The stromal expression of CD10 in breast carcinoma. J of Tokyo Med Uni 2001; 59:45-50.

Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virch Arch 2002; 440:589-93.

Puri V, Jain M, Thomas S. Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67. Int J Bre Can 2011; 2011:1-4.

Sadaka E, Almorsy W, Elsaka A. CD10 Expression as a Prognostic Factor in Female Patients with




How to Cite

Ali, H. D., Jalal, J. A., Ismail, A. T., & Alnuaimy, W. M. (2018). Stromal CD10 expression in invasive breast carcinoma. Zanco Journal of Medical Sciences (Zanco J Med Sci), 22(1), 41–48.



Original Articles